Broadwood Partners, L.P., one of the largest shareholders of STAAR Surgical Company (NASDAQ: STAA), has intensified its campaign against the board’s endorsement of a proposed acquisition by Alcon Inc. (NYSE: ALC). In a detailed letter addressed to the STAAR Surgical Board of Directors, Broadwood, which holds approximately 27.5% of all outstanding STAAR shares, questions the board’s diligence and transparency as the company moves toward a crucial shareholder vote on the $4.6 billion deal announced in August 2025.

The Proposed Acquisition

The acquisition, announced on August 5, 2025, would see STAAR Surgical, a leading developer and manufacturer of implantable lenses and related products for eye care, integrated into Alcon, a global ophthalmology and eyecare leader. The deal values STAAR at roughly $76 per share, reflecting a significant premium to STAAR’s trading price before the announcement. With the global vision care market poised for major growth—estimated by Statista to reach $190 billion by 2027—Alcon’s acquisition promises strategic synergies, expanded market reach, and strengthened innovation pipelines. Alcon has highlighted STAAR’s portfolio, notably its implantable Collamer lens (ICL) technology, as a key draw in addressing the growing demand for vision correction solutions.

Broadwood’s Concerns and Board Critique

Despite the touted benefits, Broadwood Partners has expressed deep reservations. The central concern is the pace with which the STAAR board reaffirmed its support for the acquisition, allegedly without adequate consultation with major stakeholders or a thorough market check for alternative offers. According to the letter, Broadwood asserts that “shareholders deserve a more diligent, transparent process before such a consequential decision is finalized.”

This criticism comes at a time of increased scrutiny on corporate governance practices, especially in high-value technology and healthcare acquisitions. With activist investors playing a more prominent role in shaping M&A outcomes, board diligence and fiduciary responsibility are under the microscope.

The timing of the acquisition is also a focal point of debate, as the eyecare device sector continues to attract heightened investor interest amid advances in refractive technologies and demographic trends such as global aging and rising rates of myopia. STAAR Surgical’s solid financial performance in recent quarters — posting Q2 2025 revenues of $85 million, a 15% increase year-over-year — is cited by critics as proof the company could command even greater value, either as a standalone entity or via a more competitive sale process.

Shareholder Activism and Proxy Battle

Broadwood has urged fellow shareholders to use its green proxy card to vote “AGAINST” the current sale terms, advocating for either renegotiation or renewed exploration of alternative offers. The presence of such a large, vocal dissenter underscores the heightened tension that can pervade high-stakes M&A dialogues. Proxy advisory firms, including Institutional Shareholder Services (ISS) and Glass Lewis, are closely monitoring the dispute and are expected to issue guidance leading up to the shareholder meeting.

The situation mirrors a broader uptick in shareholder activism across U.S. markets in 2025. According to Lazard, activist campaigns reached historic levels, with a record 222 companies publicly targeted globally in the first nine months of 2025. Healthcare, technology, and life sciences sectors remain particularly active, partly due to strong balance sheets, robust innovation pipelines, and shifting global healthcare demands.

Market and Industry Implications

The outcome of this engagement will reverberate across the medtech and broader healthcare sectors. STAAR Surgical has been a high-growth player, with its EVO ICL products gaining significant traction in Asia-Pacific and European markets. The acquisition by Alcon could accelerate access to global distribution networks and R&D investment, but only if it proceeds with clear, robust support from shareholders. Analysts suggest that if the deal fails, STAAR may see short-term share price volatility, though the underlying growth fundamentals remain solid.

For Alcon, successful completion would mark its largest M&A transaction since becoming an independent listed company in 2019. The integration is expected to widen its vision care product suite and reinforce its position against competitors like Johnson & Johnson Vision and Bausch + Lomb.

Looking Ahead: Corporate Governance and Deal Landscape

This ongoing contest highlights the vital role of transparent governance and open communication in major corporate transactions. Stakeholders increasingly demand rigorous review and clear strategic justification, particularly in deals involving market leaders and innovative technologies.

Shareholders are scheduled to vote on the transaction in Q4 2025. Should Broadwood’s campaign gain further traction, STAAR’s board may be compelled to reconsider its support, renegotiate terms, or even reopen the sale process. This would align with broader market trends, where empowered investors are influencing M&A outcomes at record levels heading into 2026.